Compare AMTX & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | MXCT |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.6M | 93.0M |
| IPO Year | 2023 | 2021 |
| Metric | AMTX | MXCT |
|---|---|---|
| Price | $3.53 | $0.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $12.00 | $5.50 |
| AVG Volume (30 Days) | ★ 1.6M | 699.5K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,194,000.00 | $33,026,000.00 |
| Revenue This Year | $49.77 | N/A |
| Revenue Next Year | $57.87 | $18.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 174.60 | N/A |
| 52 Week Low | $1.22 | $0.64 |
| 52 Week High | $3.66 | $2.86 |
| Indicator | AMTX | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 68.17 | 57.62 |
| Support Level | $2.17 | $0.65 |
| Resistance Level | $3.60 | $0.88 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 100.00 | 81.71 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.